Address
L.J. Zielstraweg 1
9713 GX Groningen
the Netherlands
Contact
Auke van Heel+316414128952
aukevanheel@omnicin.com
Website
Antibiotic potentiator OTX001
By potentiating existing antibiotics we can potentially offer clinicians many more treatment options when treating resistant infections.
This has the potential to be a “first in class” drug. At the used concentration our drug is not active by itself limiting resistance development.
Technology:
Microorganisms:
Application:
Development stage:
- Antimicrobial compounds
- Alternative antimicrobials
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Development
- Validation
- Research
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
Infectious disease area:
Geographic origin:
Venture Capital consortium and/or major pharmaceutical company
Omnicin Therapeutics, is an early stage pharmaceutical company, developing potentiators for existing antibiotics.
N.A.
